AZN : Enhertu Shows Survival Across Multiple HER2-Expressing Advanced Solid Tumors In Phase II Trial

(RTTNews) - Positive results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed that Enhertu (fam-trastuzumab deruxtecan-nxki) continued to demonstrate clinically meaningful and durable responses, leading to a clinically meaningful survival benefit in previously treated patients across multiple HER2-expressing advanced solid tumors, AstraZeneca (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) said in a statement.

Enhertu is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.

The companies noted that Enhertu showed a median progression-free survival of 6.9 months and median overall survival of 13.4 months in the overall trial population.

According to the companies, the results reaffirm potential role of Enhertu as a tumor-agnostic therapy for previously treated patients with HER2-expressing solid tumors and support ongoing discussions with global regulatory authorities.

For More Such Health News, visit rttnews.com